1. The Five Generations of CAR-T Architecture

The evolution of CAR-T cell design follows a clear trajectory from simple activation to intelligent, condition-specific control. Each generation introduced structural improvements that expanded therapeutic potential while addressing the clinical limitations of its predecessor from persistence failures in Generation 1 to the logic-gated precision of Generation 5.

2. Key Research Topics in CAR-T Patent Literature

The distribution of key research topics across CAR-T patent literature reveals clear clustering around core and emerging themes. Treatment of Cancer, T Cell Biology, Immune Cells, Chimeric Antigen Receptor, and Treatment of Diseases form the central pillars. CAR-T patent activity is primarily concentrated in receptor engineering, T cell biology, and oncology, especially B cell malignancies while adoptive cell therapy, combination treatments, and cell proliferation are emerging as expanding innovation frontiers.

3. Key Components of CAR-T Cell Therapy

CAR-T therapy is a multi-layered platform. The CAR construct architecture, gene delivery system, T cell chassis, and next-generation engineering strategies form an integrated system that enables engineered T cells to identify, engage, and destroy cancer cells with precision. Each component carries its own distinct patent landscape with significant IP concentration.

4. Patent Filing Trends: 2020 - 2025

CAR-T patent applications increased steadily from 356 in 2020 to a peak of 464 in 2023, before moderating to 420 in 2024 and 337 in 2025. The decline in 2025 reflects a degree of market consolidation as foundational patent positions mature — not a reduction in underlying innovation — as the field transitions toward more differentiated, next-generation claims.

5. Worldwide Distribution of Patent Activity

CAR-T patent filings are geographically concentrated in the United States and China, which together account for most of the global activity. Europe, the United Kingdom, and South Korea represent important secondary markets, while Japan, Australia, and India contribute smaller but strategically significant volumes collectively highlighting the increasingly global nature of CAR-T intellectual property.

6. Leading Patent Holders in CAR-T Cell Therapy

Patent portfolio leadership reflects significant investment by established pharmaceutical companies, specialist biotechnology firms, and academic research institutions. Bristol Myers Squibb leads with 63 patents, followed by Roche Holding, Gilead Sciences, and CRISPR Therapeutics. Academic institutions including the University of California, University of Pennsylvania, and University of Texas, are prominently featured, underscoring the deep academic roots that continue to shape the foundational IP landscape.

7. CPC Classification Analysis

The CPC classification distribution confirms the overwhelmingly oncological focus of CAR-T patent activity. A61P35/00 (antineoplastic agents) dominates with 1,167 filings more than 50% higher than the second-ranked code. A61K40/11 and A61K40/31 capture the core cell therapy mechanism, while C07K and C12N codes span receptor proteins, modified immune cell lines, and viral vectors, collectively illustrating the multi-layered nature of CAR-T intellectual property.

8. Conclusion

The CAR-T cell therapy patent landscape is experiencing rapid growth and intensifying global competition, with applications rising from 356 in 2020 to a peak of 464 in 2023, before moderating to 337 in 2025 as foundational patent positions mature. The United States and China remain the dominant jurisdictions, with Bristol Myers Squibb, Gilead Sciences, and Roche holding the strongest portfolio positions — reinforced through strategic acquisitions of Juno Therapeutics and Kite Pharma — while gene editing specialists such as CRISPR Therapeutics and Intellia Therapeutics signal the deepening convergence of CAR-T therapy with next-generation genome engineering.

CPC classification analysis confirms a strong oncological focus, with significant patent activity spanning CAR construct architecture, T cell engineering, viral vector design, and combination therapy strategies. The field is advancing beyond first-generation designs toward more sophisticated, logic-gated, and armored therapeutic constructs capable of addressing solid tumor targeting and treatment resistance.